HB 273 would create a new regulatory framework for “remote-site pharmacies” in Florida and expand the role of registered pharmacy technicians working under remote pharmacist supervision. The bill amends the definition of “pharmacy” to include remote-site pharmacies and clarifies that a pharmacy department is not considered closed when a supervising pharmacist is remotely supervising a registered technician at such a site. It also authorizes registered pharmacy technicians, in that setting, to handle sales transactions and deliver dispensed drugs under remote supervision.
The bill creates a new section of law establishing a permitting process for remote-site pharmacies. A permit applicant would need a licensed or consultant pharmacist designated as the prescription department manager, and the site would have to meet operational requirements such as 24/7 video surveillance, public notice that it is a remote-site pharmacy, written policies and procedures, controlled-substance inventory controls, and limits on when the site may operate. Remote-site pharmacies could store, hold, and dispense most medicinal drugs, including controlled substances, but could not dispense Schedule II drugs unless a pharmacist is physically present. The bill also sets a maximum supervision ratio of one pharmacist to up to six registered pharmacy technicians and authorizes the Board of Pharmacy to adopt additional rules on applications, equipment, training, and inventory storage.
HB 273 would also amend existing pharmacy laws to carve out exceptions for remote-site pharmacies from certain prohibitions that otherwise restrict nonpharmacists from filling or dispensing prescriptions. It further exempts registered pharmacists serving as prescription department managers for remote-site pharmacies from the usual limitation that a pharmacist may serve as manager at only one location. The bill is scheduled to take effect July 1, 2025.
The overall sentiment reflected in the available record is limited because there were no committee transcripts or recorded votes provided, but the bill’s introduction suggests an effort to modernize pharmacy access and expand telepharmacy operations. At the same time, the bill’s detailed safeguards indicate an emphasis on maintaining oversight, security, and controlled-substance compliance. The bill ultimately died in the Health Professions & Programs Subcommittee on June 16, 2025, indicating it did not advance despite being filed.
The main points of contention likely center on whether remote dispensing and technician-led transactions can be safely expanded without reducing patient safety or pharmacy oversight. Supporters would likely view the bill as improving access to pharmacy services, especially in underserved or after-hours settings, while opponents may be concerned about reduced in-person pharmacist presence, controlled-substance handling, and the adequacy of remote supervision. The bill attempts to address those concerns through surveillance, manager visits, operating-hour restrictions, and limits on Schedule II dispensing.
HB 273 would amend Florida’s pharmacy statutes in chapter 465 to recognize remote-site pharmacies as a distinct type of pharmacy, authorize their permitting and operation, and expand the duties that registered pharmacy technicians may perform under remote supervision. It would also modify existing prohibitions so that remote-site pharmacies and their technicians are treated differently from traditional pharmacies, while preserving pharmacist oversight requirements and adding new operational and security standards. The bill would affect pharmacies, pharmacists, pharmacy technicians, the Department of Health, and the Board of Pharmacy.
Because no committee transcripts or vote tallies are available, the public record here does not show detailed debate. The bill’s structure suggests a generally pro-access, pro-telepharmacy policy approach balanced by significant regulatory safeguards. Its failure to advance out of the Health Professions & Programs Subcommittee indicates that, whatever the merits, it did not secure enough support to move forward in the 2025 session.
The likely areas of disagreement are the expansion of remote supervision, the increased authority of registered pharmacy technicians, and the permissibility of dispensing drugs without a pharmacist physically present. Critics may question whether remote oversight is sufficient for patient safety, counseling, and controlled-substance controls, while supporters may argue the bill improves access in areas with limited pharmacist availability and modernizes pharmacy practice. The bill responds to these concerns by requiring video surveillance, written procedures, periodic manager visits, and a prohibition on dispensing Schedule II drugs unless a pharmacist is on site.